Dr. Gary Novack serves as a Clinical Development Consultant at Ceramedix, Inc. A board-certified clinical pharmacologist with deep expertise in ophthalmic drug development, he provides strategic guidance on clinical trial planning, design, and execution.
Dr. Novack brings over 45 years of experience in pharmaceutical research and development, ranging from the laboratory to the marketplace. He currently serves as President of PharmaLogic Development and Professor of Ophthalmology & Vision Science at the University of California, Davis. Throughout his illustrious career, he has consulted for hundreds of pharmaceutical and medical device firms and contributed substantially to 60+ approved products, including treatment of retinal disease. He has prepared drug development plans, clinical protocols and reports, as well as regulatory submissions such as INDs, IDEs, NDAs, PMAs, and PLAs.
Dr. Novack’s contributions to the field of ophthalmology have been recognized with prestigious awards, including the Dr. Roger Vogel Award for Pharmaceutical Research from the Association for Research in Vision and Ophthalmology (ARVO) and an Achievement Award from the American Academy of Ophthalmology (AAO). He has authored more than 420 publications spanning controlled clinical trials, clinical pharmacology, regulatory affairs, and ethics in science. He is also a member of distinguished professional societies, including ARVO, AAO, and the American Glaucoma Society. Dr. Novack received a PhD in pharmacology from UC Davis before completing a fellowship in neurophysiology at UCLA. He also holds a BA from UC Santa Cruz.